High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation - Wikidata - awgldk - TriplyDB

High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation

High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation

http://www.wikidata.org/entity/Q33941128

about

Alternative Donor Transplantation for Acute Myeloid Leukemia Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation Non-invasive Imaging of Sendai Virus Infection in Pharmacologically Immunocompromised Mice: NK and T Cells, but not Neutrophils, Promote Viral Clearance after Therapy with Cyclophosphamide and Dexamethasone Haploidentical hematopoietic transplantation without T-cell depletion: current status and future perspectives Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.Advances in graft-versus-host disease biology and therapy.Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia Novel regulatory therapies for prevention of Graft-versus-host disease.Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.Advances in treating acute myeloid leukemia.Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.The Free Radical Scavenger NecroX-7 Attenuates Acute Graft-versus-Host Disease via Reciprocal Regulation of Th1/Regulatory T Cells and Inhibition of HMGB1 Release.Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide.Hematopoietic Stem Cell Transplantation in Adult Sickle Cell Disease: Problems and Solutions.Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment.Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.Advances in the treatment of acute graft-versus-host disease.Multiple allogeneic progenitors in combination function as a unit to support early transient hematopoiesis in transplantation.Acute graft-versus-host disease: are we close to bringing the bench to the bedside?Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation.Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection.Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.Optimizing management of myelodysplastic syndromes post-allogeneic transplantation.New strategies for haploidentical transplantation.Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.Complications of allogeneic hematopoietic stem cell transplantation.Recent developments in HLA-haploidentical transplantations.Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation.Haematopoietic stem cell transplantation for sickle cell disease - current practice and new approaches.Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.Induction of Major Histocompatibility Complex-mismatched Mouse Lung Allograft Acceptance With Combined Donor Bone Marrow: Lung Transplant Using a 12-Hour Nonmyeloablative Conditioning Regimen.

P2860

Q26799456-FA2E7EB0-D2D7-46B7-88C5-1B45DFED9493 Q26852474-5FA389E9-BDAD-47F8-9EFB-F0BD4C171490 Q27312086-7782EA9F-EF11-48BB-8306-134CD46681C2 Q28080452-44E23279-D780-4775-81AB-BAA40EF5FA63 Q28732371-4E81A6E6-8FB3-4438-8535-EA892E20FA91 Q33566388-486CF186-FA1F-40C1-9FC2-65482647E3E5 Q34031916-FEB2798B-8DB6-4BBE-96D5-47B7D7D98857 Q34138598-BB5BEB3E-8676-4619-A5B5-AFB8CA9C347F Q34164154-6AC5CC2D-DA66-4F69-9F83-FC0D8963B6B4 Q34269481-18384CCD-7797-479C-92F5-7189FEF814A0 Q34293038-4855CD86-DFAF-436E-94C2-AE0CAA36FE79 Q34312351-862C8B33-EF05-4769-997D-1E2C47FFAC3C Q34684038-BF268B44-B774-4FAB-818E-EC933CB89B12 Q35505839-EBD8D06E-18B7-4102-ADBD-998C8AAA6893 Q35584266-E37A3540-A1CA-4C1B-A83B-348BE164E79D Q35609254-C281962E-0DBC-463D-BD56-2BF2C410890E Q36028504-953F9C8D-D611-4676-BE43-534EB04B2535 Q36038875-FF0C4C95-C385-42B8-8F82-776270DBDA97 Q36724916-8C33190C-B0E1-468B-B938-F5DCCC3E53A7 Q36779819-BACD98D9-571E-43E0-BAD0-9034A50BDA5B Q36833808-3C74B06A-E705-40A8-A71A-4A2A49FD34F7 Q36861714-480E4DC8-27E7-4565-B720-A878B35A8772 Q36981235-174E0B31-A057-4884-9B4E-B2B52AC71485 Q37029856-5793325A-E67B-4F58-9B5D-80C7BE835981 Q37191057-16921E6A-5901-41AF-8271-1A4906DA3820 Q37197917-8E79A887-DFF0-4AB0-BB53-AA0B2117B851 Q37402799-A519649A-774A-4434-817B-6FE2A1B8B312 Q37505854-FD17D1B0-45CF-48B3-BE45-7014C93B0BB4 Q37509207-B555DD74-9AA0-429A-96EE-309E96FF96A4 Q37842861-22816501-666E-488C-886F-CA208C280D8E Q37955235-DC338FFD-74F9-4FDC-9444-F8244A6433B1 Q37978777-BF43F692-D807-42CF-95F3-BA8892942D78 Q38190856-A03E39E2-0952-4328-B360-C38D261B3C93 Q38202155-B4589040-FE99-451B-A8F2-D514D32D6FC1 Q38217938-C6631A1C-7F01-4646-A8A4-2AC3B989D21D Q38641733-D028BFE8-54C1-4FA1-92D3-6CF851C6ED5E Q38750270-8E215133-15EC-40F1-9EA9-E6050876124A Q38851953-30E92A41-B794-4092-A219-810111FDC449 Q39153244-A57F4FF7-6137-4676-93F1-372D05BE58EF Q39176256-12650167-3C48-40A0-8452-41B2050D8129

P2860

High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation

http://www.wikidata.org/entity/Q33941128

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

High-dose, post-transplantatio ...... etic stem cell transplantation

@ast

High-dose, post-transplantatio ...... etic stem cell transplantation

@en

type

label

High-dose, post-transplantatio ...... etic stem cell transplantation

@ast

High-dose, post-transplantatio ...... etic stem cell transplantation

@en

prefLabel

High-dose, post-transplantatio ...... etic stem cell transplantation

@ast

High-dose, post-transplantatio ...... etic stem cell transplantation

@en

P1433

Q33941128-5E2F3C60-17D4-4B2A-8AF6-C6EF0730274C

P1476

Q33941128-DC267ED2-50FC-43B7-87A9-B7CDE4A821FA

P2093

Q33941128-483D913E-F72B-41DC-B5BB-09F7A0CB8801

Q33941128-4BC93B08-4B70-4DB0-939C-C37C12FC3430

P2860

Q33941128-013E39C6-6160-448E-A84A-2EDB15615E6A

Q33941128-049ED047-7250-4EEC-9E38-8F841D915A59

Q33941128-092AB5F1-A1E7-4919-B420-CD4CC21C34E5

Q33941128-0E8493A2-DEC2-45E8-A31D-077A6ED4F0E1

Q33941128-14B10EF2-6B3E-4EDF-99BB-F2EC85514C60

Q33941128-153CE557-8EE6-4751-B49C-D57B23103681

Q33941128-2063DFAD-3AC4-4A59-873A-03ADC3304372

Q33941128-2A05B328-EB95-468E-888D-33B190C657D3

Q33941128-3C8996A7-5103-4176-B1D8-398C561C6F14

Q33941128-4552CAC4-211E-4358-8234-48E529201538

P2888

Q33941128-D2185D3A-7DC8-4CD6-AC05-38BB55DFB393

P304

Q33941128-F8D0A501-6644-40F8-9A06-A7C09FAE063B

P31

Q33941128-268A75D4-8930-464F-9604-288978DDD421

P356

Q33941128-0799894C-5072-4910-A0A1-3EE71C0547F8

P433

Q33941128-5FC9907C-866C-47DD-BCCA-5CF93B600ACC

P478

Q33941128-6A06EF8A-BFB7-4448-BF57-D9A3F7B5AC67

P577

Q33941128-CE48B999-7310-4C93-A557-65774AC25386

P5875

Q33941128-32EA9653-DF0F-481A-A34F-687006D43F46

P6179

Q33941128-63839F0A-A5C6-44C1-9FA4-9BEA7CDF9496

P698

Q33941128-411EBE1F-6D64-4CF7-B196-4AD44AA725A6

P932

Q33941128-353B40AE-8CE8-4A1C-A769-C550484B88BB

P356

S12026-009-8139-0

P1433

Immunologic Research

P1476

High-dose, post-transplantatio ...... etic stem cell transplantation

@en

P2093

Ephraim J Fuchs

http://www.w3.org/2001/XMLSchema#string

Leo Luznik

http://www.w3.org/2001/XMLSchema#string

P2860

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome

Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.

The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.

Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases.

Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.

Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.

P2888

s12026-009-8139-0

P304

65-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12026-009-8139-0

http://www.w3.org/2001/XMLSchema#string

P433

1-3

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40909010

http://www.w3.org/2001/XMLSchema#string

P6179

1007380975

http://www.w3.org/2001/XMLSchema#string

P698

20066512

http://www.w3.org/2001/XMLSchema#string

P932

2892158

http://www.w3.org/2001/XMLSchema#string